Don’t reinvent the wheel — adapt it. Locate before you correct, because where a failure appears isn’t necessarily where it gets fixed.
- Closing The Gap Between Modeling And GMP Predictive Control
- Beyond The Plate Count: How To Build A Defensible Environmental Monitoring Trend Review
- What Europe's Draft Annex 22 Actually Asks Of Human Oversight Of AI
- How Is Your Glass Supplier Adapting To Europe's Energy Crisis?
- Can Peptide Mapping Predict Intact Antibody PTM Distributions?
- The EU Overhauls Pharma Laws: What You Need To Know
- An Incomplete Response: Will The FDA Finish What It Started With Real-Time CRLs?
GUEST COLUMNISTS
-
Closing The Gap Between Modeling And GMP Predictive Control
Predictive control offers opportunities to improve process consistency, reduce variability, and respond to changing manufacturing conditions before they cause deviations.
-
Beyond The Plate Count: How To Build A Defensible Environmental Monitoring Trend Review
Determining whether a drug manufacturing environment is stable, drifting, or developing a recurring loss-of-control signal requires integrated trend evaluation.
-
What Europe's Draft Annex 22 Actually Asks Of Human Oversight Of AI
The European Commission and the Pharmaceutical Inspection Co-operation Scheme (PIC/S) consulted on draft Annex 22, Artificial Intelligence. Here's what you should know.
-
How Is Your Glass Supplier Adapting To Europe's Energy Crisis?
Europe's glass manufacturers, including those making pharmaceutical lab glassware, have experienced a series of energy shocks. Many have adopted sustainability practices.
-
Can Peptide Mapping Predict Intact Antibody PTM Distributions?
Peptide mapping quantifies modification at individual sites, but the same site-level results can correspond to different distributions across intact molecules.
-
The EU Overhauls Pharma Laws: What You Need To Know
On Sept. 18, the Council of the EU published the almost-final text of a major overhaul of the EU pharmaceutical laws. The final binding text is expected to be published very soon.
-
An Incomplete Response: Will The FDA Finish What It Started With Real-Time CRLs?
FDA’s real-time CRL releases face legal and operational hurdles. Could AI-assisted redaction make transparency faster and more consistent?
BIOSIMILAR WHITE PAPERS
-
Economic Advantage Of Robotic Gloveless Pharmaceutical Isolators
Are robotic gloveless isolators the key to smarter, safer, scalable solutions? Discover how they can revolutionize aseptic filling by reducing contamination, minimizing waste, and enhancing manufacturing flexibility.
-
Solve ATMP Aseptic Filling Challenges With Gloveless Isolators1/9/2026
Human intervention is the top contamination risk in ATMP manufacturing. Robotic gloveless isolators address that risk through full automation and real-time monitoring during aseptic filling.
-
Life Cycle Assessment Of Extended Use Strategies For Single-Use Assemblies4/17/2026
Examine how extending the use of single‑use assemblies can significantly reduce emissions, resource consumption, and waste in bioprocessing, offering a data‑backed path toward sustainability.
-
ADC Manufacturing: Practices, Challenges, And The Road Ahead6/15/2026
ADCs are advancing quickly, but manufacturing complexity is rising just as fast. Key challenges in scale-up, regulation, and costs are reshaping how the next generation of therapies will be delivered.
-
Achieve Higher Targeted Concentrations9/30/2025
Single-pass TFF streamlines downstream processing by reducing footprint, shear exposure, and hold-up volumes. Learn how this approach is advancing efficiency across therapeutic and vaccine production.
-
Is Sustainability The Key To Agile Biopharma Manufacturing?3/18/2025
In biologics manufacturing, change is constant. Discover how new innovations and a focus on sustainability have gotten 62% of executives to prioritize eco-friendly practices, which reflects a commitment to long-term viability.
BIOSIMILAR APP NOTES & CASE STUDIES
BIOSIMILAR DEVELOPMENT CONTENT COLLECTIONS
The debate over whether the biosimilar regulatory paradigm can shift away from comparative efficacy trials has intensified over the past few years. This collection of articles serves as a snapshot of the many different components of this ongoing discussion.
More Content CollectionsBIOSIMILAR DEVELOPMENT NEWS
- Biocon Gets U.S. FDA Approval For Pebrilzo (pertuzumab-qcay) Injection, A Biosimilar To Perjeta, Expanding Its Oncology Portfolio
- Celltrion to Present New Analyses of OMLYCLO® (omalizumab-igec) In Chronic Spontaneous Urticaria At ACAAI 2026
- Lupin Announces European Launch Of Biosimilar Ranibizumab
- Sandoz launches Ranluspec (ranibizumab) In Europe, Providing An Affordable Treatment Option For Patients With Retinal Diseases
- Henlius Presents New Studies At ISPOR Europe 2026 To Advance Treatment Value Assessment And Global Access
- AEON Biopharma Submits IND For Comparative Pharmacodynamic Study Of ABP-450
- New Biosimilar For Patients With Certain HER2-Positive Breast Cancer Is Approved By Anvisa
- GlycoNex Announces Japanese Regulatory Submission For Denosumab Biosimilar SPD8
NEWSLETTER ARCHIVE
- 11.12.26 -- 5 Steps To Achieving Your Biosimilar Milestones On Time
- 11.05.26 -- 7 Decisions To Make Before MES Configuration
- 10.29.26 -- How Indian Biosimilar Companies Are Poised To Succeed
- 10.27.26 -- Reduce Bioprocessing Supply Risk With Manufacturing Closer To You
- 10.22.26 -- Reduce risk. Move Annex 1 forward.
